‘Bugs as drugs’: Harnessing novel gut bacteria for human health
Researchers are optimistic that a recent breakthrough allowing growth of the majority of human gut bacteria in the lab will lead to the development of new therapies for human health, replacing the use of faecal transplants in treating certain gut infections.
Scientists at the Wellcome Trust Sanger Institute in Cambridge, UK, including Dr Samuel Forster, an NHMRC C.J. Martin Biomedical Overseas Fellow from Hudson Institute’s Centre for Innate Immunity and Infectious Diseases in Melbourne, have grown and catalogued more than 130 bacteria from the human intestine according to a study published in Nature.
Understanding gut bacteria for human health
The researchers have developed a process to grow the majority of bacteria from the gut, which will enable scientists to understand how our bacterial ‘microbiome’ helps keep us healthy. Imbalances in our gut microbiome can contribute to complex conditions and diseases such as obesity, Inflammatory Bowel Disease, Irritable Bowel Syndrome and allergies. This research will allow scientists to start to create tailor-made treatments with specific beneficial bacteria.
Research in this field has expanded greatly in recent years with the intestinal microbiome being termed a ‘forgotten organ’, such is its importance to human health. Approximately two per cent of a person’s body weight is due to bacteria. Many of these bacteria are sensitive to oxygen and are difficult to culture in the laboratory, so until now it has been extremely difficult to isolate and study them.
“The bacteria in the human gut microbiota contain an equivalent number of genes as the human genome. We are only beginning to understand the ways in which gut bacteria contribute to disease spread and susceptibility, but modification of the microbiota community offers enormous potential for new therapeutics,” Dr Forster said.
Antibiotics wipe out our gut bacteria – killing both the pathogen targets and the beneficial bacteria too. There is then the potential for less desirable bacteria, such as those with antibiotic resistance, to repopulate the gut faster than the beneficial bacteria, leading to further health issues, such as Clostridium difficile infection.
Current treatment for C. difficile infection can involve transplants of faeces from healthy people, to repopulate the gut. However, this treatment is far from ideal. Using the library of new bacteria, Dr Trevor Lawley and his team at the Sanger Institute are hoping to create a pill, containing a rationally selected, defined mix of bacteria, which could be taken by patients and replace faecal transplants.
Hilary Browne, based in the Host-Microbiota Interactions Laboratory, at the Wellcome Trust Sanger Institute, explains: “It has become increasingly evident that microbial communities play a large role in human health and disease. By developing a new process to isolate gastrointestinal bacteria, we were able to sequence their genomes to understand more about their biology. We can also store them for long periods of time making them available for further research.”
Dr Forster said: “The extensive database of genomes we have generated from these gut bacteria is also essential for studying which bacteria are present or absent in people with gastrointestinal conditions. Now we can start to design mixtures of therapeutic candidates for use in these diseases.”
For the first time, the researchers also looked at the proportion of bacteria that form spores within the gut. Spores are a form of bacterial hibernation allowing some bacteria to remain dormant for long periods of time. They found approximately one third of the gut microbiota from a healthy person produced spores that allow bacteria to survive in the open air and potentially move between people. This provides a means of microbiota transmission that has not been considered before and could imply that health and certain diseases could be passed, not just through human genetics, but also via the microbiome.
Dr Lawley, group leader at the Sanger Institute said: “Being able to cast light on this microbial ‘Dark matter’ has implications for the whole of biology and how we consider health. We will be able to isolate the microbes from people with a specific disease, such as infection, cancers or autoimmune diseases, and study these microbes in a mouse model to see what happens. Studying our ‘second’ genome, that of the microbiota, will lead to a huge increase in our understanding of basic biology and the relationship between our gut bacteria and health and disease.”
Dr Forster is currently based at the Wellcome Trust Sanger Institute on an NHMRC C.J. Martin Biomedical Fellowship, and hopes to receive funding to continue his microbiota research at the Centre for Innate Immunity and Infectious Diseases at the Hudson Institute of Medical Research upon his return to Australia.
Publication | Hilary P. Browne et al. (2016). Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature. DOI: 17645.
Related publication | Samuel C. Forster et al. (2016). HPMCD: the database of human microbial communities from metagenomic datasets and microbial reference genomes. Nucleic Acids Research. DOI :10.1093/nar/gkv1216
Hudson Institute communications
t: +61 3 8572 2761